Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms of the employee share option...
All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)The expected next key milestone for UV1 is the...
NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that...
Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1.The negative INITIUM results have had important consequences for the Company....
Oslo, April 30, 2024: Ultimovacs ASA (Ultimovacs) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first...
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (Ultimovacs) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer...
Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one...
Ultimovacs previously already hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial.
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1's potential and are strongly committed to...
Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, J³nas Einarsson, Chair of the Board of Directors, has so far received proxy based...